Furthermore, CTRP3 inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner in HRMECs, suggesting the novel therapeutic potential of CTRP3 for the treatment of DR, a serious and widespread complication of diabetes. Here, C1QTNF3 is linked to diabetes mellitus.